DARZALEX (daratumumab) and DARZALEX FASPRO
Named by the company as a Q2 2026 Innovative Medicine growth driver in multiple myeloma.
What it is
Daratumumab treatment for multiple myeloma; the subcutaneous DARZALEX FASPRO form is also approved for light chain (AL) amyloidosis. It is one of the key products of the Innovative Medicine segment and the company names it as a growth driver in oncology. The company gives no dollar sales figure for it in the Q2 2026 release.↗ source
Why it matters to the stock. One of the key products in the Innovative Medicine portfolio, so its growth and any erosion affect that segment's outlook.
News
FDA approves TECVAYLI plus DARZALEX FASPRO for myeloma after one prior line, a potential second-line standard
The FDA approved TECVAYLI (teclistamab) combined with DARZALEX FASPRO for adults with relapsed or refractory multiple myeloma who have had at least one prior line of therapy.
Product